Announcements

Job offersmore »



Tweeting Growers

Top 5 - yesterday

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




Monsanto signs genome-editing licensing agreement with Broad Institute

Monsanto Company has reached a new global licensing agreement with the Broad Institute of MIT and Harvard for the use of the novel CRISPR-Cpf1 genome-editing technology in agriculture. The CRISPR-Cpf1 system has potential to be a simpler and more precise tool for making targeted improvements in a cell's DNA when compared to the CRISPR-Cas9 system.

Researchers believe that the CRISPR-Cpf1 system may offer an expanded set of benefits for advancing and delivering improved agricultural products than the CRISPR-Cas9 system. Some of these benefits include greater flexibility in the method used to edit and in the locations where edits may occur. In addition, the smaller size of the CRISPR-Cpf1 system provides researchers with more flexibility to use the genome-editing technology across multiple crops.

“The CRISPR-Cpf1 system is a powerful new discovery within the field of genome editing, and we’re excited to license the system and add it to our growing portfolio of genome-editing tools,” said Tom Adams, Ph.D., biotechnology lead for Monsanto. “This system offers a technical step-change by presenting new ways to improve crops for farmers and society alike, offering researchers greater flexibility and new capabilities using this emerging technology to improve agriculture.”

“The CRISPR-Cpf1 system represents a transformative application of genome editing for the research community,” said Issi Rozen, chief business officer of the Broad Institute. “This system can directly benefit advanced research in human health and global agriculture. We are proud to partner with stakeholders throughout the biomedical and agriculture community to help deliver responsible solutions for our planet.”

Monsanto believes that genome-editing technologies – including the CRISPR-Cpf1 system – will continue to provide a powerful tool for its research in plant breeding and biotechnology, with the promise to unlock the full potential of its world-leading germplasm and genome libraries and contribute to the development of exciting new products. The company is exploring genome editing in a phased approach across single-gene knock-outs, single-gene edits and multiple-gene edits. Over the last year, Monsanto has licensed multiple genome-editing technologies – including a separate license from the Broad Institute for use of the CRISPR-Cas9 system in agriculture – to develop a leading portfolio of tools in this field. The intellectual property around the CRISPR-Cpf1 system is independent from the CRISPR-Cas patent estate, and this CRISPR-Cpf1 license provides Monsanto with another valuable tool for genome editing in this rapidly advancing field of science.

Under the agreement, the Broad Institute grants Monsanto a worldwide non-exclusive license for agricultural applications of the CRISPR-Cpf1 system. Additional terms of the agreement were not disclosed.

For more information:
www.broadinstitute.org
monsanto.com

Publication date: 1/6/2017

 


 

Other news in this sector:

11/17/2017 Europe and China sign cooperation agreement on plant variety rights
11/16/2017 “With Caribbean, we want to offer retailers the same quality and flavour year round”
11/16/2017 US: ASTA calls for clarity on plant breeding innovation policy
11/15/2017 Seed sector renews commitment to genetic resources
11/15/2017 Global Plant Genetics introduces new berries at ExpoSE
11/15/2017 Controversy sparked in Armenia after US embassy promotes GMOs
11/14/2017 Hybrid purity testing of Brassica rapa using SSR marker technology
11/13/2017 Hong Kong: Tomatoes developed with enhanced antioxidant properties
11/13/2017 Abundant Produce launches skincare brand
11/9/2017 Frankenfood or the future of agriculture?
11/9/2017 Spain: Promotion of strategy for genetic improvement of horticultural varieties
11/9/2017 Video: Ed Currie breeds the hottest peppers in the world
11/9/2017 Bangladesh: Summer King tomato farming gets popular
11/8/2017 Artificial seeds: Even better than the real thing?
11/8/2017 Passing of "GMO Bill" sparks controversy in Uganda
11/8/2017 "We tune the breeding programmes to the entire chain"
11/6/2017 Syngenta obtains non-exclusive IP license for CRISPR-Cas9
11/1/2017 US (NC): NCBiotech Forum probes gene editing opportunities, challenges
10/30/2017 GSPP certification for Takii Europe
10/30/2017 NatureFresh and Eminent Seeds launch "world's smallest tomato"